Drug Trial Radar · NCT06077760
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
868
Planned (sponsor's estimate)
Start
Dec 6, 2023
Primary completion
Jun 25, 2030
Study completion Dec 21, 2035
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Oct 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Conditions
- Non-small Cell Lung Cancer
Interventions
Intismeran autogeneBiological
IM injection
PembrolizumabBiological
IV infusion
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease- Free Survival (DFS)Time frame: Up to ~78 months
Locations
229 sites in 33 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology ( Site 0039)
Anchorage, Alaska
The University of Arizona Cancer Center - North Campus ( Site 0071)
Tucson, Arizona
YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020)
Yuma, Arizona
UCLA Clinical & Translational Research Center (CTRC) ( Site 0059)
Los Angeles, California
Hoag Memorial Hospital Presbyterian ( Site 4042)
Newport Beach, California
Hoag Memorial Hospital Presbyterian ( Site 4048)
Newport Beach, California
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074)
Orange, California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030)
Orange, California
UCHealth Memorial Hospital-Heme Onc ( Site 0052)
Colorado Springs, Colorado
George Washington University Medical Faculty Associates ( Site 4064)
Washington D.C., District of Columbia
Mayo Clinic Florida ( Site 4043)
Jacksonville, Florida
Miami Cancer Institute at Baptist Health, Inc. ( Site 4047)
Miami, Florida
Mid Florida Hematology and Oncology Center ( Site 0014)
Orange City, Florida
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013)
Orlando, Florida
Moffitt Cancer Center ( Site 0078)
Tampa, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012)
Marietta, Georgia
Southeastern Regional Medical Center ( Site 0098)
Newnan, Georgia
Beacon Cancer Care ( Site 0044)
Post Falls, Idaho
Illinois Cancer Care ( Site 7003)
Peoria, Illinois
University of Iowa-Holden Comprehensive Cancer Center ( Site 0062)
Iowa City, Iowa
Saint Elizabeth Healthcare ( Site 0092)
Edgewood, Kentucky
The University of Louisville, James Graham Brown Cancer Center ( Site 0037)
Louisville, Kentucky
LSU Health Baton Rouge North Clinic ( Site 4040)
Baton Rouge, Louisiana
Our Lady of the Lake ( Site 4050)
Baton Rouge, Louisiana
University of Michigan Clinical Trials Office ( Site 0058)
Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan ( Site 4003)
Grand Rapids, Michigan
St. Vincent Frontier Cancer Center ( Site 0043)
Billings, Montana
NHO Revive Research Institute, LLC ( Site 4009)
Lincoln, Nebraska
Memorial Sloan Kettering - Basking Ridge ( Site 4056)
Basking Ridge, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036)
Hackensack, New Jersey
Memorial Sloan Kettering - Monmouth ( Site 4057)
Middletown, New Jersey
Memorial Sloan Kettering - Bergen ( Site 4059)
Montvale, New Jersey
Atlantic Health Morristown Medical Center ( Site 4018)
Morristown, New Jersey
New York Oncology Hematology, P.C. ( Site 4012)
Albany, New York
Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055)
Commack, New York
Memorial Sloan Kettering - Westchester ( Site 4058)
Harrison, New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095)
Mineola, New York
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053)
New York, New York
Laura and Isaac Perlmutter Cancer Center ( Site 0010)
New York, New York
Icahn School of Medicine at Mount Sinai ( Site 0034)
New York, New York
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.